Gilead Sciences (NASDAQ:GILD) Price Target Raised to $155.00

Gilead Sciences (NASDAQ:GILD) had its target price increased by Wolfe Research from $150.00 to $155.00 in a report published on Wednesday morning,MarketScreener reports. They currently have an outperform rating on the biopharmaceutical company’s stock.

GILD has been the subject of a number of other research reports. Rothschild & Co Redburn lifted their price objective on shares of Gilead Sciences from $153.00 to $159.00 and gave the company a “buy” rating in a report on Tuesday, January 20th. Needham & Company LLC boosted their price target on shares of Gilead Sciences from $133.00 to $140.00 and gave the stock a “buy” rating in a research note on Thursday, November 13th. Citigroup upped their price objective on Gilead Sciences from $140.00 to $156.00 and gave the stock a “buy” rating in a research report on Tuesday. Mizuho lifted their target price on Gilead Sciences from $131.00 to $140.00 and gave the company an “outperform” rating in a report on Friday, November 21st. Finally, HSBC upped their price target on Gilead Sciences from $110.00 to $133.00 and gave the stock a “hold” rating in a report on Wednesday, December 10th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $136.36.

Gilead Sciences Stock Performance

NASDAQ:GILD opened at $141.95 on Wednesday. The company has a market cap of $176.11 billion, a P/E ratio of 22.01, a P/E/G ratio of 0.73 and a beta of 0.33. Gilead Sciences has a twelve month low of $93.37 and a twelve month high of $142.20. The company’s 50-day moving average price is $125.36 and its 200-day moving average price is $119.59. The company has a current ratio of 1.45, a quick ratio of 1.31 and a debt-to-equity ratio of 1.03.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.16 by $0.31. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.The company had revenue of $7.77 billion during the quarter, compared to analysts’ expectations of $7.42 billion. During the same period in the prior year, the business earned $2.02 EPS. The firm’s quarterly revenue was up 3.0% on a year-over-year basis. On average, sell-side analysts forecast that Gilead Sciences will post 7.95 earnings per share for the current fiscal year.

Insider Activity

In other Gilead Sciences news, Director Kelly A. Kramer sold 2,805 shares of the business’s stock in a transaction that occurred on Friday, November 28th. The stock was sold at an average price of $127.10, for a total value of $356,515.50. Following the completion of the sale, the director owned 1,339 shares in the company, valued at approximately $170,186.90. The trade was a 67.69% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Johanna Mercier sold 3,000 shares of the firm’s stock in a transaction that occurred on Thursday, January 15th. The stock was sold at an average price of $124.31, for a total transaction of $372,930.00. Following the transaction, the insider owned 103,221 shares in the company, valued at approximately $12,831,402.51. This trade represents a 2.82% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 257,397 shares of company stock worth $33,385,512 over the last three months. Company insiders own 0.27% of the company’s stock.

Hedge Funds Weigh In On Gilead Sciences

Several institutional investors have recently bought and sold shares of the company. Personal CFO Solutions LLC increased its position in shares of Gilead Sciences by 1.7% in the fourth quarter. Personal CFO Solutions LLC now owns 4,572 shares of the biopharmaceutical company’s stock valued at $561,000 after buying an additional 76 shares in the last quarter. Moss Adams Wealth Advisors LLC grew its stake in Gilead Sciences by 1.7% in the 4th quarter. Moss Adams Wealth Advisors LLC now owns 4,446 shares of the biopharmaceutical company’s stock valued at $546,000 after acquiring an additional 76 shares during the last quarter. Valued Wealth Advisors LLC increased its holdings in Gilead Sciences by 12.5% during the 4th quarter. Valued Wealth Advisors LLC now owns 711 shares of the biopharmaceutical company’s stock valued at $87,000 after acquiring an additional 79 shares in the last quarter. SOA Wealth Advisors LLC. raised its position in Gilead Sciences by 8.7% during the fourth quarter. SOA Wealth Advisors LLC. now owns 1,016 shares of the biopharmaceutical company’s stock worth $125,000 after acquiring an additional 81 shares during the last quarter. Finally, Trivium Point Advisory LLC lifted its holdings in shares of Gilead Sciences by 1.1% in the third quarter. Trivium Point Advisory LLC now owns 7,325 shares of the biopharmaceutical company’s stock valued at $813,000 after purchasing an additional 83 shares in the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Multiple sell‑side firms raised targets and reiterated bullish ratings (Wolfe Research to $155/outperform; TD Cowen to $145/buy), reinforcing buy-side momentum and implied upside from current levels. Read More. Read More.
• Positive Sentiment: Broader analyst upgrades/positive notes from Citi, Truist, BMO and UBS add to consensus bullishness, supporting demand and higher valuation multiples. Read More.
• Positive Sentiment: Clinical/regulatory wins for Trodelvy (added to NCCN guidelines; TNBC approval/win coverage) strengthen Gilead’s oncology growth story and revenue optionality beyond antivirals. Read More. Read More.
• Positive Sentiment: Coverage pieces noting that GILD has outperformed the market and is attracting analyst attention can draw momentum and ETF/quant flows into the stock. Read More.
• Neutral Sentiment: Notes on GILD’s presence in Nasdaq/healthcare ETF lineups and elevated investor attention increase volume and liquidity but are not clear directional catalysts by themselves. Read More.
• Negative Sentiment: Insider selling: CEO Daniel Patrick O’Day sold 10,000 shares (~$1.4M) at ~$139.89 (filed on Form 4). While modest relative to his remaining holding and potentially routine, insider sales can be interpreted negatively by some investors. Read More.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.